drugset / Trial / NCT00022464

CCI-779 in Treating Patients With Metastatic Melanoma

NCT00022464

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CCI-779 in treating patients who have metastatic melanoma.

Timeline

Start
2001-06
Primary completion
2005-09
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule 250 mg Intravenous

Indications